Marksans Pharma マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Mark Saldanha

最高経営責任者

₹68.9m

報酬総額

CEO給与比率	69.7%
CEO在任期間	9.1yrs
CEOの所有権	43.8%
経営陣の平均在職期間	13yrs
取締役会の平均在任期間	6.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Marksans Pharma の収益と比較して、Mark Saldanha の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	₹3b
Jun 30 2024	n/a	n/a	₹3b
Mar 31 2024	₹69m	₹48m	₹3b
Dec 31 2023	n/a	n/a	₹3b
Sep 30 2023	n/a	n/a	₹3b
Jun 30 2023	n/a	n/a	₹3b
Mar 31 2023	₹52m	₹48m	₹3b
Dec 31 2022	n/a	n/a	₹2b
Sep 30 2022	n/a	n/a	₹2b
Jun 30 2022	n/a	n/a	₹2b
Mar 31 2022	₹38m	₹35m	₹2b
Dec 31 2021	n/a	n/a	₹2b
Sep 30 2021	n/a	n/a	₹2b
Jun 30 2021	n/a	n/a	₹3b
Mar 31 2021	₹10m	₹10m	₹2b
Dec 31 2020	n/a	n/a	₹2b
Sep 30 2020	n/a	n/a	₹2b
Jun 30 2020	n/a	n/a	₹1b
Mar 31 2020	₹10m	₹10m	₹1b
Dec 31 2019	n/a	n/a	₹879m
Sep 30 2019	n/a	n/a	₹834m
Jun 30 2019	n/a	n/a	₹780m
Mar 31 2019	₹10m	₹10m	₹804m
Dec 31 2018	n/a	n/a	₹666m
Sep 30 2018	n/a	n/a	₹582m
Jun 30 2018	n/a	n/a	₹463m
Mar 31 2018	₹12m	₹10m	₹358m

報酬と市場: Markの総報酬 ($USD 816.85K ) は、 Indian市場 ($USD 482.59K ) の同規模の企業の平均を上回っています。

報酬と収益: Markの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Mark Saldanha (52 yo)

9.1yrs

在職期間

₹68,857,053

報酬

Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Mark Saldanha	Non-Independent Executive Chairman & MD	no data	₹68.86m	43.8% ₹ 62.6b
Jitendra Sharma	Chief Financial Officer	22.2yrs	₹12.84m	データなし
Vishal Bhargava	Director Operations	no data	₹5.80m	データなし
Harshavardhan Panigrahi	Company Secretary	15.8yrs	₹2.84m	データなし
Sandra Saldanha	Whole-Time Executive Non Independent Director	10.2yrs	₹7.07m	0.073% ₹ 104.3m
Varddhman Jain	Whole-Time Executive Non Independent Director	5.8yrs	₹18.75m	データなし
Sunil Rane	Senior Vice President of QC	no data	₹10.61m	データなし
David Mohammed	Managing Director of Australia Operations	no data	データなし	データなし
Sathish Kumar	Managing Director of UK Operations	no data	データなし	データなし
Anjani Kumar	Chief Operating Officer of US Operations	no data	₹10.29m	データなし

13.0yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: 524404の経営陣は経験豊富で経験豊富です（平均在職期間は13年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Mark Saldanha	Non-Independent Executive Chairman & MD	9.1yrs	₹68.86m	43.8% ₹ 62.6b
Sandra Saldanha	Whole-Time Executive Non Independent Director	10.2yrs	₹7.07m	0.073% ₹ 104.3m
Varddhman Jain	Whole-Time Executive Non Independent Director	5.8yrs	₹18.75m	データなし
Sunny Sharma	Non-Executive & Non-Independent Director	3.3yrs	データなし	データなし
Abhinna Mohanty	Non-Executive & Independent Director	5.3yrs	₹15.00k	データなし
Shailaja Vardhan	Non-Executive & Independent Director	1.5yrs	₹300.00k	データなし
Seetharama Buddharaju	Non-Executive & Independent Director	13.1yrs	₹25.00k	データなし
Digant Parikh	Non-Executive Independent Director	6.7yrs	₹400.00k	データなし

6.3yrs

平均在職期間

53.5yo

平均年齢

経験豊富なボード: 524404の取締役会は経験豊富であると考えられます ( 6.3年の平均在任期間)。

Marksans Pharma マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Insufficient new directors

Marksans Pharma Limited, Annual General Meeting, Sep 24, 2024

Whole-time Director recently bought ₹6.9m worth of stock

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

Marksans Pharma Limited, Annual General Meeting, Aug 28, 2023

Insufficient new directors

Recent updates

Marksans Pharma Limited Receives USFDA Approval for Loratadine Tablets USP 10 mg

Price target increased by 26% to ₹330

Second quarter 2025 earnings released: EPS: ₹2.13 (vs ₹1.84 in 2Q 2024)

Marksans Pharma Limited to Report Q2, 2025 Results on Nov 12, 2024

Marksans Pharma Limited Approves Dividend for the Year Ended March 31, 2024

Upcoming dividend of ₹0.60 per share

Insufficient new directors

Now 21% overvalued after recent price rise

Successful Closure of US FDA Inspection At Marksans Pharma's Manufacturing Facility Located At Verna, Goa

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

Marksans Pharma Limited, Annual General Meeting, Sep 24, 2024

First quarter 2025 earnings released: EPS: ₹1.96 (vs ₹1.52 in 1Q 2024)

Marksans Pharma Limited to Report Q1, 2025 Results on Aug 13, 2024

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 18%

Whole-time Director recently bought ₹6.9m worth of stock

Full year 2024 earnings: EPS misses analyst expectations

Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2023-24

Marksans Pharma Limited to Report Q4, 2024 Results on May 30, 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% overvalued after recent price rise

Marksans Pharma Limited to Report Q3, 2024 Results on Feb 13, 2024

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹1.84 (vs ₹1.52 in 2Q 2023)

Marksans Pharma Limited to Report Q2, 2024 Results on Nov 09, 2023

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets

Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23

Full year 2023 earnings released: EPS: ₹6.39 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited, Annual General Meeting, Aug 28, 2023

Insufficient new directors

Investor sentiment improves as stock rises 16%

Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg

Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023

Full year 2023 earnings released: EPS: ₹6.41 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: EPS: ₹1.56 (vs ₹1.20 in 3Q 2022)

Marksans Pharma Limited to Report Q3, 2023 Results on Feb 13, 2023

Marksans Pharma Limited announced that it has received funding from OrbiMed Asia IV Mauritius FVCI Limited

Second quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.11 in 2Q 2022)

Marksans Pharma Limited to Report Q2, 2023 Results on Nov 14, 2022

Marksans Pharma Limited (BSE:524404) entered into a Business Transfer Agreement to acquire Bulk Pharmaceutical Business of Tevapharm India Private Limited.

Marksans Pharma Limited Declares Dividend, Payable on or After 20 September 2022

Upcoming dividend of ₹0.25 per share

Full year 2022 earnings released: EPS: ₹4.56 (vs ₹5.83 in FY 2021)

Marksans Pharma Limited to Report Q1, 2023 Results on Aug 13, 2022

Marksans Pharma Limited, Annual General Meeting, Aug 29, 2022

Marksans Pharma Limited Announces US FDA Approval for Pregabalin Capsules

Marksans Pharma Limited (BSE:524404) announces an Equity Buyback for INR 600 million worth of its shares.

Investor sentiment improved over the past week

Marksans Pharma Limited (BSE:524404) completed the acquisition of Access Healthcare for Medical Products LLC.

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Fiscal Year 2022 Results on May 30, 2022

Marksans Pharma Limited (BSE:524404) has signed agreement to acquire share capital of Access Healthcare for Medical Products LLC for AED 13 million.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Q3, 2022 Results on Feb 11, 2022

Second quarter 2022 earnings released: EPS ₹1.11 (vs ₹1.21 in 2Q 2021)

First quarter 2022 earnings released: EPS ₹1.51 (vs ₹1.20 in 1Q 2021)

Investor sentiment deteriorated over the past week

Marksans Pharma Limited announced that it has received INR 930.999994 million in funding from OrbiMed Asia IV Mauritius FVCI Limited and other investor

Marksans Pharma Limited announced that it expects to receive INR 930.999994 million in funding

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹5.76 (vs ₹2.95 in FY 2020)

Marksans Pharma Limited Recommends Dividend for the Financial Year Ended March 31, 2021

マネジメント基準チェック /24